Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Alnylam Pharmaceuticals stock

Own Alnylam Pharmaceuticals stock in just a few minutes.

Alnylam Pharmaceuticals, Inc is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,453 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Alnylam Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALNY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Alnylam Pharmaceuticals share price

Use our graph to track the performance of ALNY stocks over time.

Alnylam Pharmaceuticals shares at a glance

Information last updated 2021-04-30.
52-week range$119.29 - $178.41
50-day moving average $139.76
200-day moving average $141.38
Wall St. target price$174.68
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-8.25

Buy Alnylam Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alnylam Pharmaceuticals financials

Revenue TTM $492.9 million
Gross profit TTM $414.8 million
Return on assets TTM -17.85%
Return on equity TTM -69.92%
Profit margin -174.15%
Book value $8.73
Market capitalisation $16.5 billion

TTM: trailing 12 months

Shorting Alnylam Pharmaceuticals shares

There are currently 4.1 million Alnylam Pharmaceuticals shares held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 12.4% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals shares can be evaluated.

Alnylam Pharmaceuticals's "short interest ratio" (SIR)

Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals shares currently shorted divided by the average quantity of Alnylam Pharmaceuticals shares traded daily (recently around 473463.66782007). Alnylam Pharmaceuticals's SIR currently stands at 8.67. In other words for every 100,000 Alnylam Pharmaceuticals shares traded daily on the market, roughly 8670 shares are currently held short.

However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals shares, or, against the total number of tradable Alnylam Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Alnylam Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0408% of the tradable shares (for every 100,000 tradable Alnylam Pharmaceuticals shares, roughly 41 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.

Find out more about how you can short Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals share dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.

Alnylam Pharmaceuticals share price volatility

Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $119.29 up to $178.41. A popular way to gauge a stock's volatility is its "beta".

ALNY.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.2648. This would suggest that Alnylam Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site